| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2659 | 2018 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1703 | 2012 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1642 | 2015 |
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer S Johnston, J Pippen Jr, X Pivot, M Lichinitser, S Sadeghi, V Dieras, ... Journal of Clinical Oncology 27 (33), 5538-5546, 2009 | 1371 | 2009 |
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ... New England Journal of Medicine 371 (2), 107-118, 2014 | 1011 | 2014 |
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ... Journal of clinical oncology 24 (26), 4236-4244, 2006 | 880 | 2006 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 829 | 2018 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 792 | 2014 |
| High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial AJM Ferreri, M Reni, M Foppoli, M Martelli, GA Pangalis, M Frezzato, ... The Lancet 374 (9700), 1512-1520, 2009 | 772 | 2009 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 749 | 2011 |
| Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013 | 705 | 2013 |
| Capivasertib in hormone receptor–positive advanced breast cancer NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ... New England Journal of Medicine 388 (22), 2058-2070, 2023 | 699 | 2023 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 694 | 2017 |
| Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, ... New England Journal of Medicine 372 (10), 923-932, 2015 | 689 | 2015 |
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment ES Thomas, HL Gomez, RK Li, HC Chung, LE Fein, VF Chan, J Jassem, ... Journal of Clinical Oncology 25 (33), 5210-5217, 2007 | 682 | 2007 |
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma O Hamid, H Schmidt, A Nissan, L Ridolfi, S Aamdal, J Hansson, M Guida, ... Journal of translational medicine 9 (1), 204, 2011 | 661 | 2011 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 748, 2021 | 644* | 2021 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 604 | 2016 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 588 | 2014 |
| Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer A Di Leo, HL Gomez, Z Aziz, Z Zvirbule, J Bines, MC Arbushites, ... Journal of Clinical Oncology 26 (34), 5544-5552, 2008 | 583 | 2008 |
Joseph A. PintoOncosalud-AUNAVerified email at gecoperu.org
